Viridian Therapeutics (VRDN) AI Stock Analysis

• Market Cap: $1.35B
• Dividend Yield: N/A
• Average Volume (3M): 703.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.61
• Revenue Growth: 4.86%
• EPS Growth: 10.13%
• Country: US
• Employees: 143
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.87
• Shares Outstanding: 81,592,026
• 10 Day Avg. Volume: 697,007
• 30 Day Avg. Volume: 703,121
• PEG Ratio: 1.99
• Price to Book (P/B): 2.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.67
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 1.03K
• Enterprise Value/Gross Profit: -219.47
• Enterprise Value/Ebitda: -1.18
• 1Y Price Target: $38.73
• Price Target Upside: 130.67% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13

• Rating: 55 Neutral
• Price Target: $15.50 ▼(-7.68%Downside)

Viridian Therapeutics faces financial challenges with declining revenues and negative profitability, significantly impacting its overall score. However, positive corporate events, including successful trial results and strategic board appointments, provide a potential path for future growth. Technical indicators suggest moderate bullish momentum, but valuation concerns persist due to ongoing losses.

Positive Factors

Efficacy and Safety

Veligrotug's efficacy includes rapid onset and favorable safety with lower rates of hearing impairment, which is likely to drive uptake in thyroid eye disease treatment.

Market Positioning

Veligrotug shows comparable-to-better efficacy and safety with a less burdensome infusion regimen, making it a preferred IV option for Thyroid Eye Disease treatment.

Negative Factors

Financial Stability

Viridian is not yet profitable and will likely require additional funding for development and commercialization.

Regulatory and Competition Risks

Key risks include the need for regulatory approval and competition against larger organizations like Horizon.

Viridian Therapeutics Business Overview & Revenue Model

Company Description

Viridian Therapeutics, Inc. (VRDN) is a biotechnology company focused on developing transformative therapies for patients with serious diseases. The company operates primarily in the biopharmaceutical sector, leveraging cutting-edge science to address unmet medical needs. Viridian's core products are centered around innovative treatments for rare and serious conditions, particularly in the field of ophthalmology, including thyroid eye disease (TED), where they are working on developing monoclonal antibody therapy.

How the Company Makes Money

Viridian Therapeutics makes money primarily through the development and commercialization of its proprietary therapeutics. The company generates revenue through partnerships, collaborations, and licensing agreements with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on development progress, and royalties on sales of successfully developed products. Viridian's focus on rare disease therapeutics also allows it to benefit from orphan drug designations, which can provide market exclusivity and potential tax incentives. Additionally, the company may receive funding from grants and research collaborations that support its innovative pipeline.

Viridian Therapeutics Financial Statement Overview

Summary

Viridian Therapeutics is struggling financially with declining revenues, negative profitability, and cash flow challenges. Despite a strong equity position and low leverage, persistent losses and cash outflows highlight significant financial instability.

Income Statement

Viridian Therapeutics shows a declining revenue trend with a significant drop from $2,963,000 in 2021 to $302,000 in TTM 2025. The gross profit margin is negative, indicating cost of goods sold exceeds revenue. Net profit margin is also negative, reflecting substantial losses. EBIT and EBITDA margins are deeply negative, highlighting operational inefficiencies. Overall, the income statement reveals financial instability and a lack of profitability.

Balance Sheet

The balance sheet shows a strong equity position with a high equity ratio of 91.4% in TTM 2025. The debt-to-equity ratio is low, indicating minimal leverage, which is a positive aspect. However, the return on equity is negative due to consistent net losses, reflecting poor shareholder returns. Despite the strong equity base, the company faces challenges in generating profits.

Cash Flow

Operating cash flow is negative, indicating cash outflows from operations. Free cash flow is also negative, reflecting a lack of cash generation after capital expenditures. The operating cash flow to net income ratio is close to 1, suggesting cash outflows are in line with reported losses. The cash flow statement highlights liquidity challenges and the need for external financing.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	302.00K	314.00K	1.77M	2.96M	1.05M
Gross Profit	-938.00K	-1.01M	1.02M	2.34M	-27.25M
EBITDA	-265.66M	-234.56M	-128.63M	-78.79M	-109.67M
Net Income	-269.95M	-237.73M	-125.44M	-79.42M	-110.98M
Balance Sheet
Total Assets	742.40M	490.42M	435.09M	203.71M	131.25M
Cash, Cash Equivalents and Short-Term Investments	717.58M	477.37M	424.55M	196.97M	127.64M
Total Debt	21.09M	21.05M	5.26M	520.00K	455.00K
Total Liabilities	70.76M	48.40M	40.03M	15.99M	11.22M
Stockholders Equity	671.64M	442.02M	395.06M	187.72M	120.04M
Cash Flow
Free Cash Flow	-232.83M	-185.07M	-94.64M	-54.92M	-29.82M
Operating Cash Flow	-232.32M	-184.17M	-93.84M	-54.58M	-29.78M
Investing Cash Flow	-228.65M	-94.25M	-115.13M	-74.29M	-50.48M
Financing Cash Flow	457.74M	225.67M	322.24M	125.28M	101.31M

Viridian Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 16.79
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRDN, the sentiment is Positive. The current price of 16.79 is above the 20-day moving average (MA) of 15.80, above the 50-day MA of 14.76, and below the 200-day MA of 17.42, indicating a neutral trend. The MACD of 0.62 indicates Negative momentum. The RSI at 60.56 is Neutral, neither overbought nor oversold. The STOCH value of 58.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VRDN.

Viridian Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	73 Outperform	$1.17B	31.21	11.23%	―	29.20%	―
WVE	58 Neutral	$1.30B	―	-105.50%	―	-7.06%	-57.17%
VRDN	55 Neutral	$1.35B	―	-49.41%	―	4.86%	10.13%
IOVA	53 Neutral	$744.67M	―	-51.85%	―	11070.12%	32.07%
Sector *	52 Neutral	$7.37B	-0.04	-63.81%	2.59%	16.40%	<0.01%
SNDX	48 Neutral	$814.01M	―	-93.70%	―	―	-25.83%
GERN	42 Neutral	$789.78M	―	-45.35%	―	22264.23%	39.09%

Viridian Therapeutics Corporate Events

Viridian Therapeutics Stockholders Approve Key Proposals

At the Annual Meeting, Viridian Therapeutics‘ stockholders approved several key proposals, including an amendment to the 2016 Equity Incentive Plan, increasing available shares by 8,000,000. Additionally, all director nominees were elected, and KPMG LLP was ratified as the independent auditor for the fiscal year ending December 31, 2025. The approval of the 2025 Employee Stock Purchase Plan was also confirmed.

The most recent analyst rating on (VRDN) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.

Viridian Reports Positive Phase 3 Trial Results

On May 20, 2025, Viridian Therapeutics announced positive long-term durability data from its THRIVE phase 3 clinical trial for veligrotug, an anti-IGF-1R antibody for thyroid eye disease (TED). The trial showed that 70% of patients maintained their response at week 52, with no changes in safety profile. Veligrotug has received Breakthrough Therapy Designation, and the company plans a Biologics License Application submission in the second half of 2025, with a commercial launch anticipated in 2026.

The most recent analyst rating on (VRDN) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.